Özgür Tuncer

We empower people to make informed decisions about their health and lifestyle by unlocking the full potential of personal technology. Our latest innovative product will help give couples all over the world the ability to improve their chances of becoming pregnant.

Pangaea Data is headquartered in London with offices in San Francisco and Hong Kong. Pangaea’s AI-driven software product, PIES, has proven to find 6x more suitable patients including those who are undiagnosed and miscoded, improve screening success rates by 400%, and save 90% in time by automatically generating clinical narratives for regulatory reports, from tables, figures, and listings. This is achieved through Pangaeas novel unsupervised Natural Language Processing (NLP) and first-of-its-kind Natural Language Generation (NLG) methods which respectively extract and summarize intelligence from textual and multi-modal health data at scale and in a federated privacy preserving manner. Through high impact peer reviewed publications, Pangaeas product has demonstrated 85 - 90% accuracy, which is transformatively higher than generic language models like GPT-3, supervised NLP, and relational extraction approaches. The founders at Pangaea have secured more than $200 million in research funding through their work. All customer success stories and peer-reviewed publications are available through Pangaeas website.

We empower people to make informed decisions about their health and lifestyle by unlocking the full potential of personal technology. Our latest innovative product will help give couples all over the world the ability to improve their chances of becoming pregnant.

Pangaea Data is headquartered in London with offices in San Francisco and Hong Kong. Pangaea’s AI-driven software product, PIES, has proven to find 6x more suitable patients including those who are undiagnosed and miscoded, improve screening success rates by 400%, and save 90% in time by automatically generating clinical narratives for regulatory reports, from tables, figures, and listings. This is achieved through Pangaeas novel unsupervised Natural Language Processing (NLP) and first-of-its-kind Natural Language Generation (NLG) methods which respectively extract and summarize intelligence from textual and multi-modal health data at scale and in a federated privacy preserving manner. Through high impact peer reviewed publications, Pangaeas product has demonstrated 85 - 90% accuracy, which is transformatively higher than generic language models like GPT-3, supervised NLP, and relational extraction approaches. The founders at Pangaea have secured more than $200 million in research funding through their work. All customer success stories and peer-reviewed publications are available through Pangaeas website.

The Ascension Life Fund focuses on UK HealthTech and Life Sciences companies raising Seed+ funding rounds that bridge the equity gap between Seed and Series A rounds. The funds investments focus on the convergence between technology and life sciences, especially between diagnostics, personalised medicine and data science. The funds investment themes are: Healthcare Data & Platforms, Digital Therapeutics & Biomarkers, Diagnostics & Genomics, MedTech, incl. Medical Devices, Applied AI in Life Sciences & Healthcare, and Pharmaceutical Value Chain. The Ascension Life Fund has an exceptional network of advisors who assist with due diligence and the fund always looks to add value to our portfolio companies.

IMS Health has now merged with Quintiles. Visit our new website for more information www.iqvia.com